NeuroSense Therapeutics Ltd. (NRSN)

Market: NASD | Currency: USD

Address: Building B

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The Show more

📈 NeuroSense Therapeutics Ltd. Historical Chart

📊 Statistics

Analyst 1 Year Price Target: $14.00
Upside/Downside from Analyst Target: 483.33%
Broker Call: 2
Dividend Minimum 3 Year Yield: 0.00%
EPS Growth Range (1Y): 25-50%
Net Income Growth Range (1Y): 0-10%
Revenue Growth Range (1Y): -

💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for NeuroSense Therapeutics Ltd.

Date	Reported EPS
2025-06-24 (estimated upcoming)	-
2025-04-07	-0.06
2024-12-18	-0.11
2024-10-01	-0.02
2024-06-24	-0.35
2024-06-23	-0.35
2024-04-04	-0.16
2024-04-03	-0.16
2023-11-28	0.1
2023-11-27	0.1
2023-08-16	-0.44
2023-08-15	-0.44
2023-06-01	-
2023-05-31	-
2023-03-22	-
2023-03-21	-
2022-12-01	-
2022-11-30	-
2022-08-31	-
2022-08-30	-
2022-05-31	-0.24
2022-05-30	-0.24
2022-04-14	-0.24
2022-04-13	-0.24
2021-12-10	-
2021-12-09	-
2021-09-21	-
2021-09-20	-

📰 Related News & Research

No related articles found for "neurosense therapeutics".